A Tumor Cell Membrane‐Coated CD40 Ligand‐Encoding Oncolytic Adenovirus Serves as a Potent Nano‐Vaccine for Ovarian Cancer Immunotherapy

T cell reservoirs that demonstrate enhanced effector differentiation upon PD-1 checkpoint blockade. In models of peritoneal carcinomatosis, combination therapy with αPD-1 induced complete tumor eradication in 50% of mice and significantly prolonged survival. Furthermore, a synergistic efficacy was observed when the nano-vaccine was administered with cisplatin, a frontline chemotherapeutic agent. This virotherapy paradigm synergizes vaccination and immune reprogramming to dismantle immunosuppressive networks, thereby offering transformative potential against ovarian cancer.